IE45454B1 - Pharmaceutical compositions having an action on the central nervous system - Google Patents
Pharmaceutical compositions having an action on the central nervous systemInfo
- Publication number
- IE45454B1 IE45454B1 IE1509/77A IE150977A IE45454B1 IE 45454 B1 IE45454 B1 IE 45454B1 IE 1509/77 A IE1509/77 A IE 1509/77A IE 150977 A IE150977 A IE 150977A IE 45454 B1 IE45454 B1 IE 45454B1
- Authority
- IE
- Ireland
- Prior art keywords
- pharmaceutical composition
- composition according
- hydroxy
- fluoro
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 210000003169 central nervous system Anatomy 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000003176 neuroleptic agent Substances 0.000 claims abstract description 12
- 230000000701 neuroleptic effect Effects 0.000 claims abstract description 12
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 34
- 229960003878 haloperidol Drugs 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 229910052708 sodium Inorganic materials 0.000 claims description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 13
- 229960001076 chlorpromazine Drugs 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 230000003287 optical effect Effects 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 4
- 229960004940 sulpiride Drugs 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 229960004170 clozapine Drugs 0.000 claims description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002784 thioridazine Drugs 0.000 claims description 3
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical class COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- GTKYLVJCMKDNTH-UHFFFAOYSA-N 2-methoxy-5-sulfamoylbenzamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1C(N)=O GTKYLVJCMKDNTH-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 7
- 208000028017 Psychotic disease Diseases 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 229940083542 sodium Drugs 0.000 description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 208000009132 Catalepsy Diseases 0.000 description 5
- 206010047853 Waxy flexibility Diseases 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 230000002903 catalepsic effect Effects 0.000 description 2
- 230000001484 cataleptigenic effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710185409 Fusarin C synthetase Proteins 0.000 description 1
- 241000283162 Inia geoffrensis Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940067621 aminobutyrate Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7622045A FR2358881A1 (fr) | 1976-07-20 | 1976-07-20 | Composition pharmaceutique active sur le systeme nerveux central |
| FR7719390A FR2453643A2 (fr) | 1977-06-24 | 1977-06-24 | Compositions pharmaceutiques actives sur le systeme nerveux central |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE45454L IE45454L (en) | 1978-01-20 |
| IE45454B1 true IE45454B1 (en) | 1982-08-25 |
Family
ID=26219550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1509/77A IE45454B1 (en) | 1976-07-20 | 1977-07-19 | Pharmaceutical compositions having an action on the central nervous system |
Country Status (11)
-
1977
- 1977-07-18 NZ NZ184666A patent/NZ184666A/xx unknown
- 1977-07-18 IL IL52550A patent/IL52550A/xx unknown
- 1977-07-19 IE IE1509/77A patent/IE45454B1/en unknown
- 1977-07-19 GB GB30355/77A patent/GB1556567A/en not_active Expired
- 1977-07-19 CA CA283,049A patent/CA1077846A/en not_active Expired
- 1977-07-19 LU LU77796A patent/LU77796A1/xx unknown
- 1977-07-19 SE SE7708349A patent/SE7708349L/ not_active Application Discontinuation
- 1977-07-19 AU AU27151/77A patent/AU508753B2/en not_active Expired
- 1977-07-19 DE DE19772732614 patent/DE2732614A1/de not_active Withdrawn
- 1977-07-20 JP JP8785277A patent/JPS5326327A/ja active Pending
- 1977-07-20 NL NL7708055A patent/NL7708055A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ184666A (en) | 1980-04-28 |
| JPS5326327A (en) | 1978-03-11 |
| NL7708055A (nl) | 1978-01-24 |
| AU508753B2 (en) | 1980-04-03 |
| SE7708349L (sv) | 1978-01-21 |
| GB1556567A (en) | 1979-11-28 |
| LU77796A1 (enrdf_load_stackoverflow) | 1977-10-25 |
| CA1077846A (en) | 1980-05-20 |
| IE45454L (en) | 1978-01-20 |
| IL52550A0 (en) | 1977-10-31 |
| DE2732614A1 (de) | 1978-01-26 |
| AU2715177A (en) | 1979-01-25 |
| IL52550A (en) | 1981-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0402376A2 (hu) | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények | |
| UA41254C2 (uk) | ПОХІДНЕ ТЕТРАГІДРОКАРБАЗОЛУ АБО ЙОГО СІЛЬ, СОЛЬВАТ АБО ГІДРАТ ЯК АГОНІСТ 5-НТ<sub>1</sub>-ПОДІБНОГО РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ | |
| RU94034115A (ru) | Конденсированные циклические соединения и ингибиторы сквален-синтетазы | |
| ES8306707A1 (es) | "procedimiento para la preparacion de nuevos derivados de la aminometil-5-aril-3-oxazolidinona-2-" | |
| MA28020A1 (fr) | Phényl-ou pyridylamides servant d'antagonistes de la prostaglandine E2 | |
| US5196435A (en) | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma | |
| GR3023535T3 (en) | Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them | |
| ATE152445T1 (de) | 3,5-dioxo-(2h,4h)-1,2,4-triazine als 5ht1a ligande | |
| BR0307406A (pt) | Indóis substituìdos como agonistas alfa-1 | |
| AU4306796A (en) | Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs | |
| MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
| ES538418A0 (es) | Un derivado de indol-3-carboxamida | |
| ATE250573T1 (de) | Azetidin- und pyrrolidinderivate | |
| AU2003269923A8 (en) | 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors | |
| MY205137A (en) | Novel tricyclic aromatic heterocyclic compound, preparation method therefor, pharmaceutical composition and application thereof | |
| NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
| MX9306310A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| BR9509353A (pt) | Utilzação de diazepino-indolas as respectivas diazepino- indolas e medicamen to | |
| IE45454B1 (en) | Pharmaceutical compositions having an action on the central nervous system | |
| SE9102909L (sv) | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) | |
| BRPI0508404A (pt) | derivado de (indol-3-il)-heterociclo, composição farmacêutica, uso de um derivado de (indol-3-il)-heterociclo, e método de tratamento da dor | |
| KR950700879A (ko) | 신규한 퍼히드로 이소인돌 유도체 및 이들의 제조(Novel perhydroisoindole derivatives and preparation thereof) | |
| GB1336743A (en) | S-triazolo-1,5-a- 1,4- benzodiazepine derivatives and a process for their preparation | |
| ATE274496T1 (de) | Pharmazeutische zusammensetzungen welche aryl- substituierte olefinische amin-verbindungen enthalten | |
| ATE181734T1 (de) | N-benzoylmethylsubstituierte paroxetinderivate |